НачалоЗа лекариDiscontinuation rate of dapoxetine in patients with lifelong premature ejaculation: 1-year observational study

Свързани статии

alkaly 235

urorenal 235


Genov P. 1 , Kolev N. 2 , Dunev V. 2 , Stoykov B. 2 , Vanov A. 2 , Atanasov J. 2

1MHAT Ruse, Dept. of Urology, Ruse, Bulgaria, 2UMHAT "Georgi Stranski", Dept. of Urology, Pleven, Bulgaria


Introduction & Objectives: Premature ejaculation is the most common sexual dysfunction in men, however it is not well understood. Although Dapoxetine is the only oral pharmacological agent approved for the treatment of premature ejaculation, which is considered a "gold standard" and a first choice agent with high efficacy, the incidence of discontinuation of treatment with it is very high. Our aim was to investigate the discontinuation rate of Dapoxetine in patients with premature ejaculation and the reasons for stopping treatment in real practice.

 Materials & Methods: 78 patients with lifelong premature ejaculation were included in the study by taking 30 or 60 mg Dapoxetine as needed. and were followed for 1 year. The mean age of the patients was 29 (18-46) years. Patient visits to clinics were at 3, 6 and 12 months. The patients discontinuation rates from treatment and the reasons for this were assessed.

 Results: Of all patients, only 18.5% continue treatment for the entire 1-year period. The cumulative treatment discontinuation rates at 3, 6 and 12 months were respectively 34.1%, 69.6% and 81.5% . It is noteworthy that 69.6% of patients stop their treatment in the first 6 months. The reasons for discontinuation of treatment that patients refers are: 19.5% high costs, 38.1% disappointment that premature ejaculation is an incurable disease and that Dapoxetine is needed to be taken every time sexual intercourse is contemplated, 12.3% due to undesirable medication effects, 20.3% due to dissatisfaction with the treatment effect and 9.8% due to the search for other treatment options.

Conclusions: The rate of discontinuation of Dapoxetine treatment is very high. The main reasons for the discontinuation are the high costs and the disappointment that it has always been necessary to take the medicine when planning sexual intercourse, which that does not allow patients to be spontaneous. In the future, alternative methods of treatment should be sought in patients with lifelong premature ejaculation.

Eur Urol Suppl 2017; 16(11);e2830

Добавете коментар

Защитен код

zapazete chas 2